News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK) Taking A Break From Dealmaking: CEO


5/8/2014 8:09:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Hours after Ken Frazier announced the biggest deal he’s made in three years as Merck & Co.’s leader, he cautioned investors not to expect any quick follow-ups. “We’re not serial mergers and acquirers,” Frazier said in an interview after his Whitehouse Station, New Jersey-based based company announced it had sold its over-the-counter business to Bayer AG (BAYN) for $14.2 billion. During a time when competitor Pfizer Inc. (PFE) has reorganized its company, divested two units about the same size as Merck’s OTC business and announced it was pursuing a $100-billion-plus deal that may be the biggest ever in the industry, Frazier is preaching patience.

Help employers find you! Check out all the jobs and post your resume.

Read at Bloomberg

comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES